FDA approved Zourri, a product of UroGen Pharma Ltd, on August 8, 2025, marking a significant milestone for the company.
3 reports, 2 independent
Updated Aug 8
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA approved Zourri, a product of UroGen Pharma Ltd, on August 8, 2025, marking a significant milestone for the company.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Zusduri, a product of Urogen Pharma, is gaining market traction against competitors like MSD's Keytruda and Ferring's Adstiladrin.Sub-event
FDA approved Zourri, a product of UroGen Pharma Ltd, on August 8, 2025.1 source
Keep exploring
The entities involved
Related events
- ADC Therapeutics is seeking accelerated approval from the FDA for its Zynlonta therapy.
- The FDA is actively monitoring adherence to FSSAI guidelines, leading inspections of Zomato's Hyperpure unit and Zepto warehouses regarding food safety compliance.
- The FDA recommended advancement for a new drug application submitted by a company.
- Intellia Therapeutics is seeking FDA approval for its drug Lonvo-Z.
- The FDA is reviewing a drug approval application for a condition involving the company GAD.
Coverage
Newest first; wire copies grouped- GuruFocus.comUroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ... Release Date: August 07, 2025 For the complete transcript of the earnings call, please refer to the full
- GlobeNewswireUroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results ZUSDURI™ (mitomycin) for intravesical solution now available as the first and only
- GlobeNewswireUroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscl